Based on our test panels composition of allergen extracts and molecular allergens, a near complete picture of each patient’s sensitization status is obtained. ALEX² is based on our proprietary nano-bead technology. Every allergen (extract) can be individually optimized for production. The flexible analysis software, allows our customers to analyze tailormade allergen panels as they see fit for their clinical needs – Multiplex on demand.

The ALEX² assay protocol integrates a powerful Cross-reactive Carbohydrate Deteminants (CCDs) inhibitor during serum incubation, which will clear up your specific IgE results. This reduces the interpretative burden for physicians of CCD positive patients and increases the specificity of our test results.

Simultaneous measurement of total and specific IgE
Near-complete allergen panel, individually optimized
Multiplex test with on-demand panel composition
Integrated CCD inhibition

ALEX² is the next generation in vitro test for type I allergies. With an allergen panel of close to 300 allergen extracts and molecular allergens complemented by total IgE, we aim at above 99 % coverage of all routine diagnostic needs.

Our patent-pending technology was designed for testing hundreds of allergens in parallel without accepting a compromise on the performance of any single parameter.

The ALEX² assay protocol integrates a powerful Cross-reactive Carbohydrate Determinants (CCDs) inhibitor during serum incubation, which will clear up your specific IgE results. This reduces the interpretative burden for physicians of CCD positive patients and increases the specificity of our test results.

The quantification is based on a colorimetric image acquisition, using CMOS sensors and instrumentation.